Text Size

PET FDG Assessment of Change in Atherosclerotic Plaques After Chemotherapy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2008 by Tel-Aviv Sourasky Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT00742352
First received: August 25, 2008
Last updated: September 8, 2008
Last verified: August 2008
History of Changes
  Purpose

The purpose of this study is to determine whether chemotherapy induces regression in atherosclerotic plaques in oncologic patients already undergoing PET FDG as part of their routine assessment.We will use PET FDG to assess whether the inflammation in atherosclerotic plaques is affected by chemotherapy and anti angiogenic therapy.


Condition
Atherosclerosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

MedlinePlus related topics: Atherosclerosis
U.S. FDA Resources

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Estimated Enrollment: 40
Study Start Date: September 2008
Groups/Cohorts
Breast cancer patients
Lung cancer patients

  Eligibility

Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Breast cancer patients at the Tel-Aviv Sourasky Medical Center Lung cancer patients at the Tel-Aviv Sourasky Medical Center

Criteria

Inclusion Criteria:

  • Women over the age of 65 diagnosed with metastatic breast cancer
  • Men over the age of 65 diagnosed with lung cancer

Exclusion Criteria:

  • Patients under the age of 65
  • Patients diagnosed with chronic inflammatory disease or chronic infection
  • Patients taking steroids and NSAIDS on a regular basis
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00742352

Contacts
Contact: Einat Even Sapir, MD PhD 972-3-6973532 evensap@tasmc.health.gov.il

Locations
Israel
Tel-Aviv Sourasky Medical Center Not yet recruiting
Tel Aviv, Israel, 64239
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
  More Information

No publications provided

Responsible Party: Prof. Einat Even-Sapir, Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier: NCT00742352     History of Changes
Other Study ID Numbers: TASMC-08-EES-253-CTIL
Study First Received: August 25, 2008
Last Updated: September 8, 2008
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Atherosclerosis
Plaque, Atherosclerotic
Arteriosclerosis
Arterial Occlusive Diseases
 Vascular Diseases
Cardiovascular Diseases
Pathological Conditions, Anatomical

ClinicalTrials.gov processed this record on May 16, 2013